ICON PLC

ICLR Healthcare Diagnostics & Research

ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.

Revenue
−2.86%
EPS
+143.2%
Free cash flow
−8.01%
Total debt
−0.86%

Quarter to September 2026, against a year earlier

201.62 1.49 −0.73%
Market cap
$15.1B
P/E
34.5×
Fwd P/E
34.6×
Dividend yield
—
F-score
6/9
Altman Z
2.01
Beneish M
−2.62
Dividend safety
n/a

ICON PLC (ICLR) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, ICON PLC (ICLR) trades at a P/E ratio of 34.5×. Over the past ten years it has ranged from 14.7× (May 2016) to 307× (July 2026); the current reading is higher than 67% of that period. That is in line with the Diagnostics & Research industry median of 34.5× and above the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 66.1× 182.55%
FY2024 23.4× (37.86%)
FY2023 37.6× 20.36%
FY2022 31.3× (69.60%)
FY2021 103× 227.17%
FY2020 31.4× 25.08%
FY2019 25.1× 15.98%
FY2018 21.7× (1.72%)
FY2017 22.1× 42.01%
FY2016 15.5× (18.24%)

Quarterly newest first

Period P/E ratio Change
Sep 2026 29.1× (90.17%)
Jun 2026 296× 492.72%
Mar 2026 49.9× (24.48%)
Dec 2025 66.1× 26.24%
43 more quarters

Against its own ten years

Low 14.7× High 307×
Ten-year median 25.0×
Current reading's percentile 64

P/E ratio against peers

Company P/E ratio
GH Guardant Health, Inc. compare n/m
DGX Quest Diagnostics Incorporated compare 25.0×
QGEN QIAGEN N.V. compare 26.1×
LH Labcorp Holdings Inc. compare 29.5×
ICLR ICON PLC 34.5×
MEDP Medpace Holdings, Inc. compare 34.6×
ILMN Illumina, Inc. compare 35.6×
RVTY Revvity Inc. compare 71.9×
CRL Charles River Laboratories International, Inc. compare 300×
Diagnostics & Research industry median 34.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on ICLR